The bill amends RCW 70.14.100 and RCW 70.14.110 to revise procedures and requirements for the state health technology assessment program. It directs the administrator, working with participating agencies and the health technology clinical committee, to select technologies for review according to specified priorities (including alignment with federal Medicare coverage and nationally recognized expert treatment guidelines, concerns about safety, efficacy, or cost‑effectiveness, high or expected state expenditures, and availability of adequate evidence). Selection may occur on petition from interested parties, and historical limits for the first and second years after June 7, 2006 (up to six and eight technologies respectively) are retained in the text as shown. The bill requires the administrator to contract with an evidence‑based practice center (AHRQ‑designated or other appropriate entity) to conduct systematic assessments of safety, efficacy, and cost‑effectiveness, with assessments to be initiated no sooner than 30 days after online notice of selection. The committee must consider the assessment in an open process with public comment, may form ad hoc advisory groups whose members have civil liability immunity for good faith official acts, and must give greatest weight to the most valid and reliable evidence while accounting for sex, age, ethnicity, race, and disability. For life‑threatening or rare diseases the committee must evaluate all applicable clinical trials in peer‑reviewed literature and, where applicable, consider expert information about trial design ethics or feasibility. Committee determinations must be consistent with federal Medicare decisions and expert guidelines unless substantial evidence supports a contrary determination, must be reconsidered at least every 18 months when new evidence could change a prior decision, and the health care authority must post receipt of submissions within 30 days and complete and communicate determinations (including written rationale for adverse determinations) within 180 days of initial submission. The provided text references roles and other statutory sections (administrator, participating agencies, committee, RCW 70.14.130, and how participating agencies implement coverage decisions or how conflicts of interest terms are specified) but does not define those terms or provide the full implementation and appeal details; those definitions and procedural specifics are not included in the extracted facts.

If enacted, the bill creates a predictable, evidence-focused process that will steer which medical technologies state health programs cover and under what conditions. The administrator and the health technology clinical committee will prioritize technologies aligned with federal Medicare decisions or expert guidelines, require contracted, systematic assessments by designated evidence centers, and use specific timelines (receipt posted within 30 days, assessments begin no sooner than 30 days after posting, committee decisions and written explanations delivered within 180 days, and re-reviews at least every 18 months). In practice this will likely shift coverage decisions toward interventions supported by the strongest available evidence, change patient access to certain technologies, and require the state to fund and manage external assessments. The entities most affected are the state participating agencies that run purchased health care programs (they will need to follow the committee’s coverage determinations and use the committee’s medical necessity criteria), the administrator and health care authority (responsible for contracting, publishing notices, and meeting timelines), the evidence centers contracted to perform reviews, and patients/enrollees whose benefits may be added, limited, or clarified. Advisory group members get civil liability immunity but must meet conflict-of-interest terms. Important details are missing here: the specific identities of the named “administrator” and “participating agencies,” current limits on selections beyond the historical caps cited, and how agencies must implement or appeal coverage changes are not included in the provided text.